All Pharma News
Kyverna To Attend AAN With KYV-101 Neuro Autoimmune Data

Kyverna To Attend AAN With KYV-101 Neuro Autoimmune Data
PR NEWSWIRE
11 Apr 2024
Share Share
Kyverna Provides Business Update and Reports FY23 Financial Results

Kyverna Provides Business Update and Reports FY23 Financial Results
PR NEWSWIRE
26 Mar 2024
Share Share
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101
PR NEWSWIRE
07 Mar 2024
Share Share
Kyverna Therapeutics Announces Closing of Initial Public Offering

Kyverna Therapeutics Announces Closing of Initial Public Offering
PR NEWSWIRE
12 Feb 2024
Share Share
Kyverna CEO: `We`re in the next phase of medicine`

Kyverna CEO: `We`re in the next phase of medicine`
FIERCE BIOTECH
09 Feb 2024
Share Share
Kyverna overshoots raised IPO expectations with $319M offering

Kyverna overshoots raised IPO expectations with $319M offering
FIERCE BIOTECH
08 Feb 2024
Share Share
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
PR NEWSWIRE
07 Feb 2024
Share Share
Kyverna raises IPO expectations to almost $300M

Kyverna raises IPO expectations to almost $300M
FIERCE BIOTECH
06 Feb 2024
Share Share
Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials

Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials
ENDPTS
01 Feb 2024
Share Share
Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials

Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
FIERCE BIOTECH
01 Feb 2024
Share Share